Skip to main content

August 2013 - FRMC

08/15/2013
The FDA approved tazarotene foam for acne vulgaris based on the results of two, phase 3 studies conducted in the US and Canada. 
The FDA approved tazarotene foam for acne vulgaris based on the results of two, phase 3 studies conducted in the US and Canada. 
The FDA approved tazarotene foam...
08/15/2013
First Report Managed Care
08/15/2013
Chicago—Of patients with chronic myeloid leukemia (CML) who are treated with tyrosine-kinase inhibitors (TKIs), 20% to 30% develop resistance to the drugs; others are intolerant.
Chicago—Of patients with chronic myeloid leukemia (CML) who are treated with tyrosine-kinase inhibitors (TKIs), 20% to 30% develop resistance to the drugs; others are intolerant.
Chicago—Of patients with chronic...
08/15/2013
First Report Managed Care
08/15/2013
Chicago—After 2 years of treatment, 43% of patients with advanced melanoma who received nivolumab were alive, according to a phase 1 study. The 1-year overall survival rate was 62%, and median overall survival was 16.8 months. All patients...
Chicago—After 2 years of treatment, 43% of patients with advanced melanoma who received nivolumab were alive, according to a phase 1 study. The 1-year overall survival rate was 62%, and median overall survival was 16.8 months. All patients...
Chicago—After 2 years of...
08/15/2013
First Report Managed Care
08/15/2013
Chicago—A broad perspective of disease burden and impact of treatment may be gained utilizing patient-reported outcomes (PROs) such as health-related quality of life (HRQoL). For patients with multiple myeloma (MM) and other hematologic...
Chicago—A broad perspective of disease burden and impact of treatment may be gained utilizing patient-reported outcomes (PROs) such as health-related quality of life (HRQoL). For patients with multiple myeloma (MM) and other hematologic...
Chicago—A broad perspective of...
08/15/2013
First Report Managed Care
08/15/2013
Chicago—At a minimum of 15 months follow-up, patients with unresectable, metastatic BRAF wild-type melanoma who received 24 mg of lenvatinib once daily had a median progression-free survival of 3.7 months and a median overall survival of 9.5...
Chicago—At a minimum of 15 months follow-up, patients with unresectable, metastatic BRAF wild-type melanoma who received 24 mg of lenvatinib once daily had a median progression-free survival of 3.7 months and a median overall survival of 9.5...
Chicago—At a minimum of 15...
08/15/2013
First Report Managed Care
08/15/2013
Chicago—According to a survey, most oncologists and hematologists have faced drug shortages in recent years and have had to deny, delay, or modify treatment regimens for cancer patients. Although the scarcity of these drugs has received...
Chicago—According to a survey, most oncologists and hematologists have faced drug shortages in recent years and have had to deny, delay, or modify treatment regimens for cancer patients. Although the scarcity of these drugs has received...
Chicago—According to a survey,...
08/15/2013
First Report Managed Care
08/15/2013
Patients with moderate-to-severe chronic low back pain who received 12 weeks of treatment with the Butrans® (buprenorphine) transdermal system had significant improvements in several activities of daily living compared with a placebo group.
Patients with moderate-to-severe chronic low back pain who received 12 weeks of treatment with the Butrans® (buprenorphine) transdermal system had significant improvements in several activities of daily living compared with a placebo group.
Patients with moderate-to-severe...
08/15/2013
First Report Managed Care
08/15/2013
An analysis of a claims database found that 61% of patients with diabetic peripheral neuropathy had not received treatment for the disease.Although if patients took medications, they typically used opioids to manage the condition.
An analysis of a claims database found that 61% of patients with diabetic peripheral neuropathy had not received treatment for the disease.Although if patients took medications, they typically used opioids to manage the condition.
An analysis of a claims database...
08/15/2013
First Report Managed Care
08/15/2013
There are limited options available for the treatment of irritable bowel syndrome with constipation, but linaclotide has recently been approved.
There are limited options available for the treatment of irritable bowel syndrome with constipation, but linaclotide has recently been approved.
There are limited options...
08/15/2013
First Report Managed Care

Department

Conference Insider
08/15/2013
Fort Lauderdale—In the United States, approximately 100 million adults have chronic pain, which is associated with $275 billion in healthcare costs and $300 billion in lost worker productivity each year. The combined costs are larger than...
Fort Lauderdale—In the United States, approximately 100 million adults have chronic pain, which is associated with $275 billion in healthcare costs and $300 billion in lost worker productivity each year. The combined costs are larger than...
Fort Lauderdale—In the United...
08/15/2013
First Report Managed Care